Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Inc

XERS

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.46B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Xeris Biopharma Holdings IncXeris Biopharma Holdings Inc-87.3-176%8.5-29.7
$12.00

Target Price by Analysts

40.7% upsideXeris Biopharma Holdings Target Price DetailsTarget Price
$2.89

Current Fair Value

66.1% downside

Overvalued by 66.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.46 Billion
Enterprise Value$1.63 Billion
Dividend Yield$- (-)
Earnings per Share$0
Beta0.85
Outstanding Shares172,823,455

Return

Return on Equity176.34%ROE
Return on Assets-4.17%
Return on Invested Capital0.71%

Valuation & Multiples

P/E Ratio-87.33P/E Ratio
PEG-5.77PEG
Price to Sales8.53Price to Sales
Price to Book Ratio-8.53Price to Book Ratio
Enterprise Value to Revenue4.86
Enterprise Value to EBIT1036.66
Enterprise Value to Net Income-96
Total Debt to Enterprise0.18
Debt to Equity-29.74Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 6, 2026
EPS Estimate
$0.01
Average shareholder expectation
Revenue Estimate
$90.13 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 5, 2026
EPS Estimate
$0.02
Average shareholder expectation
Revenue Estimate
$101.56 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.6435▼ 5.11%
Total Calls875,400▲ 6.68%
Total Puts563,300▼ 1.18%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %65.09%▲ 1.70%
Total Invested$1.05B▲ 72.47%
Investors Holding249▲ 5.00%

ESG Score

No data

About Xeris Pharmaceuticals Inc

CEO: paul Edick